Lung Cancer Diagnostics Market Size and Forecast 2026–2034

Introduction

The global healthcare industry is witnessing a transformative shift toward early disease detection and personalized medicine, and lung cancer diagnostics are at the center of this evolution. Lung cancer remains one of the most common and deadly cancers worldwide, accounting for a significant proportion of cancer-related deaths each year. As healthcare systems prioritize early diagnosis and targeted treatment strategies, the demand for accurate and efficient diagnostic technologies has grown substantially.

According to Renub Research, the Lung Cancer Diagnostics Market is projected to grow from US$ 13.2 Billion in 2025 to US$ 27.4 Billion by 2034, expanding at a Compound Annual Growth Rate (CAGR) of 7.21% from 2026 to 2034. This strong growth trajectory reflects rising cancer incidence, technological breakthroughs in diagnostic tools, and increasing government initiatives aimed at early cancer screening.

Download Sample Report

The integration of advanced imaging technologies, molecular diagnostics, artificial intelligence, and next-generation sequencing is enabling healthcare providers to detect lung cancer earlier and more accurately than ever before. Combined with increasing awareness of preventive healthcare, these innovations are expected to significantly reshape the landscape of cancer diagnostics over the next decade.

Lung Cancer Diagnostics Market Overview

Lung cancer diagnostics encompass a wide range of medical procedures and tests designed to detect, identify, and monitor lung cancer. These diagnostic approaches allow physicians to determine the presence of cancer, classify its type, and identify genetic mutations that influence treatment decisions. Early diagnosis plays a critical role in improving patient survival rates and enabling timely therapeutic interventions.

Traditional diagnostic methods include imaging techniques such as chest X-rays, computed tomography (CT) scans, positron emission tomography (PET) scans, and magnetic resonance imaging (MRI). These technologies allow healthcare professionals to detect abnormal growths or tumors in lung tissues.

In addition to imaging, biopsy procedures, sputum cytology tests, and molecular diagnostics are widely used to confirm the presence of cancer and identify its biological characteristics. Molecular testing has become particularly important in modern oncology because it helps identify specific genetic mutations, allowing clinicians to recommend targeted therapies.

Recent innovations such as liquid biopsy and next-generation sequencing (NGS) are further transforming the diagnostic landscape. These advanced techniques provide less invasive and highly accurate methods of detecting cancer biomarkers in blood samples, enabling earlier detection and improved monitoring of disease progression.

The increasing adoption of precision medicine, along with improvements in healthcare infrastructure and diagnostic technologies, is expected to drive sustained demand for lung cancer diagnostics worldwide.

Growth Drivers of the Lung Cancer Diagnostics Market

Rising Global Prevalence of Lung Cancer and Smoking-Related Diseases

One of the most significant factors driving the lung cancer diagnostics market is the growing global incidence of lung cancer. The disease remains a leading cause of cancer-related mortality worldwide, largely associated with smoking, air pollution, occupational exposure, and unhealthy lifestyles.

In India, for example, lung cancer cases are projected to rise from 63,708 cases in 2015 to 81,219 cases by 2025. With nearly 100 million adult smokers in the country and increasing exposure to environmental pollutants, the risk of lung cancer continues to grow. Alarmingly, around 80–85% of patients are diagnosed at advanced stages, leading to approximately 60,000 deaths annually.

This rising disease burden has increased the demand for effective screening programs and advanced diagnostic technologies capable of detecting cancer in its earliest stages. Early detection significantly improves survival outcomes and allows physicians to initiate treatment before the disease progresses.

Governments and healthcare organizations around the world are therefore encouraging screening programs, particularly for high-risk populations such as smokers, the elderly, and individuals exposed to environmental pollutants. Growing awareness about preventive healthcare is also motivating individuals to undergo regular screenings, further driving demand for lung cancer diagnostics.

Technological Advancements in Diagnostic Techniques

Rapid advancements in medical technology have significantly enhanced the accuracy and efficiency of lung cancer diagnostics. Modern imaging technologies such as low-dose computed tomography (LDCT), PET scans, and high-resolution imaging systems allow clinicians to detect small lung abnormalities that might otherwise go unnoticed.

At the same time, molecular diagnostics and genetic testing are enabling physicians to identify specific cancer mutations, allowing for personalized treatment strategies. These technologies have become essential in precision medicine, where therapies are tailored to the genetic characteristics of individual tumors.

Artificial intelligence is also emerging as a powerful tool in cancer diagnostics. AI-driven algorithms can analyze imaging data with remarkable accuracy, assisting radiologists in detecting early signs of lung cancer and reducing diagnostic errors.

A notable development occurred in May 2025, when Johnson & Johnson MedTech partnered with Qure.ai to enhance early lung cancer detection in India. This collaboration integrates artificial intelligence with medical imaging technologies to identify cancer at highly treatable stages, demonstrating how technology partnerships are shaping the future of diagnostics.

As these innovations continue to evolve, diagnostic procedures are becoming faster, less invasive, and more reliable, which is expected to drive further market growth.

Growing Adoption of Early Screening Programs

The increasing emphasis on preventive healthcare has led many countries to implement national lung cancer screening programs. These initiatives focus on identifying cancer in its earliest stages, particularly among high-risk populations.

Early detection is crucial because lung cancer often develops silently without noticeable symptoms until it reaches advanced stages. Screening programs using low-dose CT scans have proven highly effective in identifying early-stage tumors, significantly improving treatment outcomes.

For instance, Taiwan’s National Lung Cancer Early Detection Program, launched in 2023, successfully identified 85% of lung cancer cases at stage 0 or stage 1. This demonstrates the critical role of screening initiatives in enabling early intervention and reducing mortality rates.

As more governments and healthcare organizations invest in similar programs, participation in cancer screening is expected to rise. This growing awareness and accessibility are likely to boost demand for diagnostic technologies across the globe.

Challenges in the Lung Cancer Diagnostics Market

High Cost of Advanced Diagnostic Technologies

Despite technological advancements, the high cost of advanced diagnostic equipment remains a major challenge for the global lung cancer diagnostics market.

Imaging systems such as CT scanners, PET scanners, and advanced molecular testing platforms require significant investments for purchase, installation, and maintenance. These costs can place a heavy financial burden on healthcare facilities, particularly in low- and middle-income countries.

Patients may also face substantial expenses associated with diagnostic procedures, including imaging tests, biopsies, and genetic analysis. In regions where health insurance coverage is limited, these costs can discourage individuals from seeking early diagnosis.

To address this issue, healthcare providers and policymakers are exploring strategies such as increased insurance coverage, government funding for screening programs, and technological innovations aimed at reducing diagnostic costs.

Limited Access to Diagnostic Infrastructure in Developing Regions

Another challenge facing the lung cancer diagnostics market is the uneven distribution of healthcare infrastructure across different regions. Many developing countries lack sufficient diagnostic laboratories, imaging facilities, and trained healthcare professionals capable of performing complex diagnostic procedures.

Limited awareness about lung cancer symptoms and screening programs also contributes to delayed diagnosis. In many cases, patients seek medical attention only after the disease has progressed to advanced stages, reducing the effectiveness of treatment.

Addressing these gaps will require significant investments in healthcare infrastructure, training programs for medical professionals, and initiatives aimed at increasing public awareness about early cancer detection.

Key Market Segments

Lung Cancer Biopsy Diagnostics Market

Biopsy diagnostics play a critical role in confirming lung cancer by analyzing tissue samples obtained from the lungs. Several types of biopsies are used depending on the tumor’s location and the patient’s condition, including needle biopsies, bronchoscopy biopsies, and surgical biopsies.

Advancements in biopsy technology have improved diagnostic accuracy while reducing procedure-related complications. Modern biopsy techniques are less invasive and allow for faster recovery times, making them an essential component of lung cancer diagnosis and personalized treatment planning.

Lung Cancer Molecular Test Diagnostics Market

Molecular diagnostics are becoming increasingly important in lung cancer management. These tests identify genetic mutations such as EGFR, ALK, and other biomarkers that influence treatment decisions.

By identifying these mutations, physicians can select targeted therapies that improve treatment effectiveness while minimizing side effects. The rise of precision medicine has therefore significantly increased the demand for molecular testing in oncology.

Small Cell Lung Cancer Diagnostics Market

Small Cell Lung Cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly. Accurate and timely diagnosis is essential for initiating treatment and improving survival outcomes.

Advanced imaging technologies and molecular testing methods are increasingly used to detect SCLC at earlier stages. Growing awareness of early cancer detection and ongoing research in diagnostic technologies are expected to drive continued growth in this segment.

Lung Cancer Diagnostic Imaging Centers Market

Diagnostic imaging centers play a crucial role in lung cancer detection by providing advanced imaging services such as CT scans, PET scans, X-rays, and MRI. These centers often offer faster and more accessible diagnostic services compared to traditional hospital settings.

The expansion of cancer screening programs and rising awareness about early detection are fueling demand for imaging services worldwide.

Lung Cancer Hospital-Associated Laboratories Market

Hospital-associated laboratories are responsible for conducting critical diagnostic tests, including biopsy analysis, molecular testing, and pathology examinations.

These laboratories enable rapid communication between clinicians and laboratory specialists, ensuring accurate diagnosis and timely treatment decisions. As hospitals continue to adopt advanced laboratory technologies, their role in lung cancer diagnostics will become even more significant.

Regional Market Insights

United States

The United States remains one of the most advanced markets for lung cancer diagnostics, supported by a strong healthcare infrastructure and widespread adoption of cutting-edge technologies.

In July 2025, the U.S. FDA approved the Oncomine Dx Express Test, an NGS-based companion diagnostic designed to detect EGFR exon 20 insertion mutations in non-small cell lung cancer patients. The test can deliver genomic results in less than 24 hours, demonstrating the rapid technological progress in cancer diagnostics.

United Kingdom

The United Kingdom is witnessing steady growth in lung cancer diagnostics due to strong government support and national healthcare programs focused on early detection.

In January 2026, Optellum was selected for a groundbreaking NHS initiative integrating AI-driven lung cancer risk assessment with robotic bronchoscopy, enabling more accurate and less invasive diagnostic procedures.

India

India’s lung cancer diagnostics market is expanding rapidly as healthcare infrastructure improves and awareness about cancer screening increases.

In November 2025, Yashoda Hospital in Hyderabad, in collaboration with Qure.ai and AstraZeneca, launched an AI-powered Lung Nodule Clinic designed to detect lung cancer at early stages and improve treatment outcomes.

Saudi Arabia

Saudi Arabia is investing heavily in healthcare modernization and cancer care services. Government initiatives to improve diagnostic capabilities and expand healthcare facilities are contributing to the growth of lung cancer diagnostics in the region.

Competitive Landscape

Leading companies operating in the global lung cancer diagnostics market include:

Illumina

Abbott Laboratories

Thermo Fisher Scientific, Inc.

QIAGEN N.V.

Roche Holding AG

Sanofi S.A.

Agilent Technologies

bioMérieux

These companies focus on research and development, technological innovation, and strategic collaborations to expand their diagnostic portfolios and strengthen their market presence.

Final Thoughts

The lung cancer diagnostics market is entering a period of rapid growth as healthcare systems prioritize early detection and personalized treatment strategies. With the market expected to reach US$ 27.4 Billion by 2034, the role of advanced diagnostic technologies will become increasingly vital in the global fight against cancer.

Innovations such as artificial intelligence, liquid biopsy, and next-generation sequencing are revolutionizing how lung cancer is detected and monitored. At the same time, expanding screening programs and rising awareness about preventive healthcare are encouraging more individuals to undergo early diagnostic testing.

While challenges such as high costs and limited infrastructure remain, ongoing technological advancements and increased investment in healthcare systems are expected to overcome these barriers.

Ultimately, the future of lung cancer diagnostics lies in precision medicine, early detection, and global accessibility—a combination that has the potential to significantly improve patient outcomes and reduce the global burden of lung cancer.